PhotoPharmics Phase 2 Parkinson’s Disease
April 16, 2026
PhotoPharmics will be attending the American Academy of Neurology Annual Meeting (AAN) in Chicago, April 18-22. PhotoPharmics’ pivotal Phase 3 Light for Parkinson’s Disease clinical trial is in its final weeks, and topline results will likely be shared at the World Parkinson Congress in late May. This fully remote, randomized, double-blind, placebo-controlled study is evaluating Celeste®, an investigational photo-neuromodulation device, in individuals living with Parkinson’s disease.
If you’ll be at AAN, drop by the PhotoPharmics Booth, #3614.
Recent News
- Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA Initiation in Adults with IBS-C
- Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
- Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
- Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
- BlueWind Medical Announces Humana Coverage of Revi® for Urgency Urinary Incontinence, Expanding Access to Millions of Patients
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
